synthetic lethality

Zentalis lays off 40% to fund registrational trial of WEE1 drug

The FDA’s move to lift the hold on Zentalis’ clinical-stage drug may have been good news for the biotech—but it’s been bad news for some of its staff.

James Waldron Jan 29, 2025 4:42am

pay deal hand over cash licensing transaction money

BeiGene inks $150M deal to follow cancer trail blazed by Amgen

Dec 13, 2024 9:11am

Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules

Nov 6, 2024 8:28am

Repare lays off 25% of staff as biotech halts preclinical R&D

Aug 29, 2024 6:36am

MA strategy deal block push come together form

Ideaya bags option on Biocytogen bispecific ADC in $400M deal

Jul 31, 2024 9:04am

Tango drops USP1 inhibitor over liver toxicity in phase 1 trial

May 23, 2024 8:11am